Sirna Posts Higher Revenues, Lower Losses in Third Quarter
Sirna Therapeutics reported this week a rise in third-quarter revenues, which helped drive down losses in the period.
For the third quarter of 2005, Sirna's revenues were $1.9 million, up from $84,000 in the year-ago period. Sirna attributed the increase to a $1.8-million milestone payment from Eli Lilly under the companies' oncology collaboration.
Sirna's net loss in the quarter fell to $4.2 million, or $0.08 per share, from $7.8 million, or $0.21 per share, a year earlier.